-
Mashup Score: 1Life after CAR-T: Clinical outcomes of patients with MM who relapse after BCMA-targeted CAR T-cell therapy - 2 year(s) ago
At the 2021 International Myeloma Workshop (IMW21) in September, Oliver Van Oekelen, from the Parekh Lab at the Icahn School of Medicine at Mount Sinai, presented data regarding the outcomes of patients with multiple myeloma (MM) who have relapsed following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell therapy (CAR-T),1 which we have summarized herein.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Life after CAR-T: Clinical outcomes of patients with MM who relapse after BCMA-targeted CAR T-cell therapy - 2 year(s) ago
At the 2021 International Myeloma Workshop (IMW21) in September, Oliver Van Oekelen, from the Parekh Lab at the Icahn School of Medicine at Mount Sinai, presented data regarding the outcomes of patients with multiple myeloma (MM) who have relapsed following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell therapy (CAR-T),1 which we have summarized herein.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⌛ In case you missed it ⌛ 🔎 ICYMI: Oliver Van Oekelen gave an informative presentation on outcomes of RRMM following CAR T-cell therapy at #IMW21, which we have summarized on the #myeloma hub 👉 https://t.co/zh8rEjpzmS 👈 #mmsm https://t.co/cjUjQ1iZ0n
-
-
Mashup Score: 4Life after CAR-T: Clinical outcomes of patients with MM who relapse after BCMA-targeted CAR T-cell therapy - 2 year(s) ago
At the 2021 International Myeloma Workshop (IMW21) in September, Oliver Van Oekelen, from the Parekh Lab at the Icahn School of Medicine at Mount Sinai, presented data regarding the outcomes of patients with multiple myeloma (MM) who have relapsed following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell therapy (CAR-T),1 which we have summarized herein.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔎 ICYMI: @ovanoekelen gave an informative presentation on outcomes of RRMM following CAR T-cell therapy at #IMW21, which we have summarized on the #myeloma hub 👉 https://t.co/zh8rEjpzmS 👈 #mmsm https://t.co/Ue2ivVDapK
-
-
Mashup Score: 0
Considerable advances have been made in the treatment of multiple myeloma (MM) over the past 2 decades, including alternatives to alkylator-based induction regimens and the addition of novel agents such as daratumumab, elotuzumab, ixazomib, pomalidomide, and panobinostat, among others.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚 Read about the main arguments exposed by @End_myeloma and @PLMcCarthyMD at #IMW21 defending the importance of treatment-free interval vs maintenance therapy in first line. #mmsm 👉 https://t.co/ytcuMbWc4Y 👈 https://t.co/9yHOfdV7cS
-
-
Mashup Score: 2Treatment-free intervals for patients with myeloma - 3 year(s) ago
Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, Birmingham, AL, talks on whether it is possible to…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Should patients with #Myeloma be given treatment-free intervals? Luciano Costa (@End_myeloma) of @UABNews discusses both sides of the argument ⚖️ Watch here : 👉https://t.co/YEeumVehkX👈 @Myeloma_Society #IMW2021 #IMW21 #MultipleMyeloma #MMsm #HemOnc
-
-
Mashup Score: 1Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple Myeloma - 3 year(s) ago
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma. @MyelomaOslo @Myeloma_Society | #mmsm #IMW21 https://t.co/CHhq0Wii35 https://t.co/k3VFhYNqV7
-
-
Mashup Score: 1Fredrik Schjesvold, MD, PhD, Discusses Adjustments in the Treatment of Myeloma During the COVID-19 Pandemic - 3 year(s) ago
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the Oslo Myeloma Center .
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop discusses patient declines rates during #COVID19. #IMW21 | @Myeloma_Society @MyelomaOslo https://t.co/MoNFBLaEeh https://t.co/P6gYnWuSUQ
-
-
Mashup Score: 0Fredrik Schjesvold, MD, PhD, Discusses Adjustments in the Treatment of Myeloma During the COVID-19 Pandemic - 3 year(s) ago
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the Oslo Myeloma Center .
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the @MyelomaOslo. #IMW21 | @Myeloma_Society https://t.co/MoNFBLaEeh
-
-
Mashup Score: 2
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with #mmsm. #IMW21 | @Myeloma_Society https://t.co/7RUVrRoemh https://t.co/LNYra1bo8L
-
-
Mashup Score: 1Luciano Costa, MD, PhD, Discusses Topline Data Utilizing KRd in Newly Diagnosed Myeloma - 3 year(s) ago
CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma. #IMW21 | @End_myeloma @Myeloma_Society https://t.co/fT2303U5Tx https://t.co/Fapr8BEirK
-
👀 Catch up on this 👀 🔎 ICYMI: Oliver Van Oekelen gave an informative presentation on outcomes of RRMM following CAR T-cell therapy at #IMW21, which we have summarized on the #myeloma hub 👉 https://t.co/zh8rEjpzmS 👈 #mmsm https://t.co/01f0txDizf